Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary

Aikou Okamoto; Rosalind M. Glasspool; Seiji Mabuchi; Noriomi Matsumura; Hiroyuki Nomura; Hiroaki Itamochi; Masashi Takano; Tadao Takano; Nobuyuki Susumu; Daisuke Aoki; Ikuo Konishi; Alan Covens; Jonathan Ledermann; Delia Mezzazanica; Christopher Steer; David Millan; Iain A. Mcneish; Jacobus Pfisterer; Sokbom Kang; Laurence Gladieff; Jane Bryce; Amit Oza

doi:10.1097/IGC.0000000000000289

Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary

Aikou Okamoto, Rosalind M. Glasspool, Seiji Mabuchi, Noriomi Matsumura, Hiroyuki Nomura, Hiroaki Itamochi, Masashi Takano, Tadao Takano, Nobuyuki Susumu, Daisuke Aoki, Ikuo Konishi, Alan Covens, Jonathan Ledermann, Delia Mezzazanica, Christopher Steer, David Millan, Iain A. Mcneish, Jacobus Pfisterer, Sokbom Kang, Laurence GladieffJane Bryce, Amit Oza

Obstetrics & Gynecology

Research output: Contribution to journal › Review article › peer-review

66 Citations (Scopus)

Abstract

Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than highgrade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/ carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/ JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.

Original language	English
Pages (from-to)	S20-S25
Journal	International Journal of Gynecological Cancer
Volume	24
Issue number	9
DOIs	https://doi.org/10.1097/IGC.0000000000000289
Publication status	Published - 11-2014

All Science Journal Classification (ASJC) codes

Oncology
Obstetrics and Gynaecology

Access to Document

10.1097/IGC.0000000000000289

Fingerprint Dive into the research topics of 'Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary'. Together they form a unique fingerprint.

Cite this

Okamoto, A., Glasspool, R. M., Mabuchi, S., Matsumura, N., Nomura, H., Itamochi, H., Takano, M., Takano, T., Susumu, N., Aoki, D., Konishi, I., Covens, A., Ledermann, J., Mezzazanica, D., Steer, C., Millan, D., Mcneish, I. A., Pfisterer, J., Kang, S., ... Oza, A. (2014). Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 24(9), S20-S25. https://doi.org/10.1097/IGC.0000000000000289

Okamoto, Aikou ; Glasspool, Rosalind M. ; Mabuchi, Seiji ; Matsumura, Noriomi ; Nomura, Hiroyuki ; Itamochi, Hiroaki ; Takano, Masashi ; Takano, Tadao ; Susumu, Nobuyuki ; Aoki, Daisuke ; Konishi, Ikuo ; Covens, Alan ; Ledermann, Jonathan ; Mezzazanica, Delia ; Steer, Christopher ; Millan, David ; Mcneish, Iain A. ; Pfisterer, Jacobus ; Kang, Sokbom ; Gladieff, Laurence ; Bryce, Jane ; Oza, Amit. / Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary. In: International Journal of Gynecological Cancer. 2014 ; Vol. 24, No. 9. pp. S20-S25.

@article{85de6bad192c4179bc45a6aa8e7e3cf1,

title = "Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary",

abstract = "Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than highgrade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/ carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/ JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.",

author = "Aikou Okamoto and Glasspool, {Rosalind M.} and Seiji Mabuchi and Noriomi Matsumura and Hiroyuki Nomura and Hiroaki Itamochi and Masashi Takano and Tadao Takano and Nobuyuki Susumu and Daisuke Aoki and Ikuo Konishi and Alan Covens and Jonathan Ledermann and Delia Mezzazanica and Christopher Steer and David Millan and Mcneish, {Iain A.} and Jacobus Pfisterer and Sokbom Kang and Laurence Gladieff and Jane Bryce and Amit Oza",

year = "2014",

month = nov,

doi = "10.1097/IGC.0000000000000289",

language = "English",

volume = "24",

pages = "S20--S25",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

Okamoto, A, Glasspool, RM, Mabuchi, S, Matsumura, N, Nomura, H, Itamochi, H, Takano, M, Takano, T, Susumu, N, Aoki, D, Konishi, I, Covens, A, Ledermann, J, Mezzazanica, D, Steer, C, Millan, D, Mcneish, IA, Pfisterer, J, Kang, S, Gladieff, L, Bryce, J & Oza, A 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary', International Journal of Gynecological Cancer, vol. 24, no. 9, pp. S20-S25. https://doi.org/10.1097/IGC.0000000000000289

Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary. / Okamoto, Aikou; Glasspool, Rosalind M.; Mabuchi, Seiji; Matsumura, Noriomi; Nomura, Hiroyuki; Itamochi, Hiroaki; Takano, Masashi; Takano, Tadao; Susumu, Nobuyuki; Aoki, Daisuke; Konishi, Ikuo; Covens, Alan; Ledermann, Jonathan; Mezzazanica, Delia; Steer, Christopher; Millan, David; Mcneish, Iain A.; Pfisterer, Jacobus; Kang, Sokbom; Gladieff, Laurence; Bryce, Jane; Oza, Amit.

In: International Journal of Gynecological Cancer, Vol. 24, No. 9, 11.2014, p. S20-S25.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary

AU - Okamoto, Aikou

AU - Glasspool, Rosalind M.

AU - Mabuchi, Seiji

AU - Matsumura, Noriomi

AU - Nomura, Hiroyuki

AU - Itamochi, Hiroaki

AU - Takano, Masashi

AU - Takano, Tadao

AU - Susumu, Nobuyuki

AU - Aoki, Daisuke

AU - Konishi, Ikuo

AU - Covens, Alan

AU - Ledermann, Jonathan

AU - Mezzazanica, Delia

AU - Steer, Christopher

AU - Millan, David

AU - Mcneish, Iain A.

AU - Pfisterer, Jacobus

AU - Kang, Sokbom

AU - Gladieff, Laurence

AU - Bryce, Jane

AU - Oza, Amit

PY - 2014/11

Y1 - 2014/11

N2 - Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than highgrade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/ carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/ JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.

AB - Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than highgrade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/ carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/ JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.

UR - http://www.scopus.com/inward/record.url?scp=84922377545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922377545&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000289

DO - 10.1097/IGC.0000000000000289

M3 - Review article

C2 - 25341576

AN - SCOPUS:84922377545

VL - 24

SP - S20-S25

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -